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Francesco Marincola1 and Philip Dooner2*Introduction
We are delighted to announce the launch of Transla-
tional Medicine Communications (TMC), a companion
journal to Journal of Translational Medicine [1]. With
the National Center for Advancing Translational Sci-
ences (NCATS) currently developing its first strategic
plan to “identify critical challenges, compelling oppor-
tunities, and emerging and unmet needs; develop and
set scientific and operational goals and research prior-
ities; and engage a diverse and broad community of
stakeholders” [2], the time has never been better to
launch a journal that will be a home for the translational
sciences community.
The open access nature of TMC has many advantages
including free and universal online access to the article
immediately upon publication, giving it the potential to
reach a much larger audience than any subscription-
based journal. Copyright is also retained by the author.
Being an online only journal, there are also no page or
color charges and we can host unlimited numbers of fig-
ures, data sets and movies. A single Article Processing
Charge (APC) is applied to all articles, regardless of their
length and we aim to ensure that the APC is always
competitive and affordable.Scope
TMC aims to publish open access research, as well as re-
view, methodology and protocol articles that facilitate
the communication between basic and clinical science.
Like Journal of Translational Medicine, TMC covers all
areas of translational medicine and retains its specialised
sections.
TMC also believes that all scientifically valid research
deserves to be published and made accessible to the
translational research community.* Correspondence: philip.dooner@biomedcentral.com
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As mentioned previously, TMC is the companion journal
to Journal of Translational Medicine and shares a similar
scope and many of the same Editorial Board Members.
However, unlike Journal of Translational Medicine,
which aims to publish articles contributing to the signifi-
cant advancement of translational science, TMC only as-
sesses a manuscript’s suitability for publication based on
its scientific validity.
Because TMC is led by the same expert editorial team
as Journal of Translational Medicine, it means that man-
uscripts submitted to Journal of Translational Medicine,
but not of sufficient advance to warrant publication, may
be deemed suitable for publication in TMC prior to sub-
mission. In these instances, it is possible to transfer the
manuscript files and any reviewer comments automatic-
ally and the Editor should be able to make a decision, or
give guidance about revision, without sending the manu-
script out for another round of review.Peer review
TMC uses the same team of specialised Section Editors,
each one an expert in their own field.
The journal aims to provide authors with a first deci-
sion on their manuscript within six weeks. Upon sub-
mission, manuscripts are assigned to one of the Section
Editors, or one of the journal’s knowledgeable Deputy
Editors, Senior Editors or Associate Editors. Each hand-
ling editor will critically assess the manuscript, and when
appropriate provide necessary detailed input. The manu-
script will also be assessed by two independent referees
as standard.
The aim of the peer review process is to establish the
soundness of a manuscript. Referees and Editors will de-
termine whether a paper is scientifically valid, rather
than making judgements on interest levels or whether
the submission represents a significant advance.
The journal editors will try and keep the number of
major revision requests to a minimum, and limit
requesting unnecessary further experiments.le is distributed under the terms of the Creative Commons Attribution 4.0
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